205 related articles for article (PubMed ID: 32796402)
1. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME
Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402
[TBL] [Abstract][Full Text] [Related]
2. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
4. Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.
Matossian MD; Elliott S; Hoang VT; Burks HE; Phamduy TB; Chrisey DB; Zuercher WJ; Drewry DH; Wells C; Collins-Burow B; Burow ME
PLoS One; 2017; 12(8):e0177802. PubMed ID: 28771473
[TBL] [Abstract][Full Text] [Related]
5. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
7. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
[TBL] [Abstract][Full Text] [Related]
8. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
9. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
11. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
13. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
14. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
17. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
19. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
20. Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
Yamashita D; Minata M; Ibrahim AN; Yamaguchi S; Coviello V; Bernstock JD; Harada S; Cerione RA; Tannous BA; La Motta C; Nakano I
Mol Cancer Ther; 2020 May; 19(5):1134-1147. PubMed ID: 32127468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
